Close Menu

NEW YORK (GenomeWeb) – Biocept said yesterday that it has closed a previously announced $10 million public offering.

The company sold 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million shares at a combined offering price of $1.10 per share.

Underwriters also partially exercised an over-allotment, purchasing warrants for up to 627,131 additional shares of common stock at $0.0009 per warrant. These warrants are exercisable immediately at a price of $1.10 per share and will expire five years from the date of issuance, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.